CHARACTERIZATION OF P53 ABNORMALITIES IN B-CLL PATIENTS IN RELATION TO IGVH MUTATION STATUS AND PREVIOUS TREATMENT

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F05%3A00019164" target="_blank" >RIV/00216224:14110/05:00019164 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

CHARACTERIZATION OF P53 ABNORMALITIES IN B-CLL PATIENTS IN RELATION TO IGVH MUTATION STATUS AND PREVIOUS TREATMENT

Original language description

Background: Although the defects in the p53 gene predispose B CLL patients for inferior outcome, little is known about the reasons leading to inactivation of this tumor-suppressor. The p53 abnormalities were reported to be associated with unmutated IgVHsubtype and may thus arise as a consequence of its more aggressive behaviour, but some reports point also to potentially damaging chemotherapy including alkylating agents (Sturm et al., Cell Death Differ 2003; 10: 477 to 484). Aims: The aims of the studywere to determine the spectrum of p53 mutations in B CLL patients treated or monitored at our center and to correlate the data to mutation status of IgVH and to the previous treatment. Methods: We analyzed the status of the p53 gene in 144 patients diagnosed with B CLL of all stages using functional analysis in yeasts (FASAY) supplemented by Western blotting detection of p53 protein expression and I FISH detection of p53 deletions (LSI p53 17p13.1). We used PCR and direct sequencing to

Czech name

Charakterizace p53 abnormalit u B-CLL pacientů ve vztahu k mutačnímu statusu IgVH a předchozí léčbě

Czech description

Background: Although the defects in the p53 gene predispose B CLL patients for inferior outcome, little is known about the reasons leading to inactivation of this tumor-suppressor. The p53 abnormalities were reported to be associated with unmutated IgVHsubtype and may thus arise as a consequence of its more aggressive behaviour, but some reports point also to potentially damaging chemotherapy including alkylating agents (Sturm et al., Cell Death Differ 2003; 10: 477 to 484). Aims: The aims of the studywere to determine the spectrum of p53 mutations in B CLL patients treated or monitored at our center and to correlate the data to mutation status of IgVH and to the previous treatment. Methods: We analyzed the status of the p53 gene in 144 patients diagnosed with B CLL of all stages using functional analysis in yeasts (FASAY) supplemented by Western blotting detection of p53 protein expression and I FISH detection of p53 deletions (LSI p53 17p13.1). We used PCR and direct sequencing to

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NR8445" target="_blank" >NR8445: In vitro sensitivity/resistance of CLL cells with inactivated p53 on modern therapy</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2005

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Blood

ISSN

0006-4971

e-ISSN

—

Volume of the periodical

2005

Issue of the periodical within the volume

11

Country of publishing house

US - UNITED STATES

Number of pages

1

Pages from-to

—

UT code for WoS article

—

EID of the result in the Scopus database

—